Bad News for Blood Thinners?


Earlier this week, Motley Fool health-care bureau chief Brenton Flynn discussed Johnson & Johnson's failed attempt to get its blood thinner Xarelto approved by the FDA for a lucrative new treatment area. In this video, Brenton tells us about one headwind that could potentially impact sales of blood thinners across the board. If a device coming out from Boston Scientific to prevent blood clots due to atrial fibrillation receives approval in the U.S., it could be worth half a billion dollars for the company, and could slightly weigh on blood thinner sales, if successful. Brenton tells us which companies could be affected by this under-the-radar trend.

Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.

The article Bad News for Blood Thinners? originally appeared on

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.